YouTube.com/user/JoeRC2007 ... Written by Julie Brown & Kurt Koehler ... JULIE BROWN (Julie/co-writer/producer), is thrilled that Homecoming Queen is now a ...
8.30 am â. Presentation 1 â Assessing the impact of biochar in the Herbert cane Industry. Group: The Biochar Grower Group of Lannercost. Presenter: Lawrence ...
in texture. The overture is light and graceful - the lower "earth-bound" cellos and double basses ... Sugar Plum Fairy is, perhaps, the best known of all the dances in the suite - its fairy-like atmosphere conjured up by .... TROMBONE. Ross Bliim*.
Sep 26, 2014 - Paloma Miratvilles, Universitat of Barcelona (Spain). Fariza Achcaoucaou, Universitat of Barcelona (Spain). Ana NÃºÃ±ez-Carballosa, Universitat ...
Outcomes of Abolitionism in Post-Revolutionary Mexico City, 1929-1952.â David Reid (Rutgers University) â âFighting the Revolution: Popular Protest, State .... emancipation and equality are often used as a way to measure suitability for members
Page 2 ... Szt who effectively invented the solo piano recital. ... mood and tempo. ... the trumpets, difficult to manage in G minor, do not appear; there are no.
Dec 10, 2010 - and designer, director Master Design at Domus Academy), Clementine ... Grima (Publishing Director Domus magazine), Alessandro Guerriero ...
Mar 22, 2014 - another pre-conference workshop for your skills development on the topic ...... âDiet type and changes in food cravings following weight loss: ...... 28% of those seeking gastric bypass surgery suffer from NES ...... before surgery.
Oct 3, 2018 - Deep Reinforcement Learning. 16:00-16:30 Coffee break. 16:30-18:30 Andreas Krause and Felix Berkenkamp. Towards Safe Reinforcement ...
An accomplished clarinetist and pianist, she received her Bachelor of Music Degree with .... hall, with his acclaimed Rhapsody in Blue premier- ing in 1924.
7th SUMMER SCHOOL ON MEDECINES 7e ÉCOLE D’ÉTÉ EN DÉVELOPPEMENT DU MÉDICAMENT www.SSM7.org
UNIVERSITÉ DE MONTRÉAL MONTRÉAL QUÉBEC (Canada)
June 14-19, 2015
SSM7 offers a unique 40-hour training program on drug discovery, development and market access under a multicultural sponsorship in the wonderful setting of Montreal, Quebec. Make plans now for one full week of lively presentations and direct interactions with the Faculty, including Case Studies and Workshops with Industry, covering the whole value chain of medicines, from “idea to market”. SSM7 Faculty members are leaders in their field and contribute to create one of the most innovative and focused programs in drug discovery & development currently offered.
Opening Note Dear participants to SSM7, On behalf of the Université de Montréal, it’s a real pleasure for me to welcome you at this 7th edition of the Summer School of medicines. We’re honoured to organize this summer school in collaboration with two of our privileged international academic partners, the University of Barcelona and Université Paul Sabatier in Toulouse. For several years now, this summer school has represented an important international outreach for us in our mission to train the next generation of scientists in the biopharmaceutical sector. U de Montreal is the 2th largest research U in Canada, with more than 62 thousands students attending, and over 400M Euro in research funding each year. In North America, the region of Montreal is ranked 6th among the major hubs of Biopharmaceutical research. Of the four innovative medicines ever developed in Canada and approved by the American FDA, all were developed in the region of Montreal. Drug discovery is serious business. It has impact on economics, politics, ethics and most importantly on people. Patients who suffer from diseases we don’t yet fully understand. As you will appreciate this week, developing new drugs that are safe and effective is one of the most difficult challenges facing mankind. It involves science, lots of it, in so many different fields that nobody can do it alone in his or her lab. We need specialists that can see the big picture and understand the language of other specialists, their challenges and opportunities, from idea to market. This is why we are here. To give you the larger picture. Because it is an international school, with faculty and students coming from several countries in the European Union and North America, SSM7 is also an opportunity to make contacts and build your network. Do not hesitate to ask questions either after talks or during the general discussions that will follow at the end each day. Several speakers will stay with us after their talk so see this as an opportunity to meet and discuss with them. We wish you all the best learning experience possible with SSM7.
Denis deBlois Chairman, SSM7 Scientific and Organizing Committee for Members of the Scientific and Organizing Committee (www.SSM7.org) Brian White-Guay, U de Montréal (www.umontreal.ca) Pierre Cordelier, U Paul-Sabatier / INSERM, Toulouse Oncopole (www.oncopole-toulouse.com) Remy Poupot, , Université Paul-Sabatier / INSERM, Toulouse Oncopole (www.oncopole-toulouse.com) Jordi Quintana, Parc Cientific Barcelona (PCB) (www.pcb.ub.edu) Sara Babic, Biocat, Barcelona, (www.biocat.ca)
SSM7– UNIVERSITE DE MONTREAL – JUNE 14-19, 2015
Program SUNDAY, June 14, 2015
Pavilion Jean-Coutu, room S1-111 15:00 – 16:00 Registration 16:00 – 16:15 OFFICIAL OPENING – 7th Summer School on Medicines (SSM7) Denis de Blois, Université de Montréal, Québec, Chairman, SSM7 Brian White-Guay, Université de Montréal, Québec Jordi Quintana, Parc Cientific Barcelona (PCB) Pierre Cordelier, Université Paul-Sabatier / INSERM, Toulouse Remy Poupot, , Université Paul-Sabatier / INSERM, Toulouse 16:15 – 17:15 Keynote Lecture 1 : Dendrogenin A: a tumor suppressor metabolite and an example of transfer from academia to the industry Marc Poirot, Inserm / CNRS / Université Paul Sabatier 17:15 – 18:15 Keynote Lecture 2 : The challenge of developing a therapy for an orphan disease as a Canadian startup: the story of Enobia Philippe Crine, Founder and CSO, Enobia Pharma 18:15 – 20:00 Welcome Reception at Pavilion Jean-Coutu
MONDAY, June 15, 2015
Pavilion Jean-Coutu, room S1-111 SESSION I : DRUG R&D, AN OVERVIEW FROM IDEA TO MARKET Chairperson: Denis deBlois, Université de Montréal, Québec 8:45 – 10:15 Drug Discovery overview Denis deBlois, Université de Montréal, Québec 10:15 – 10:30 Health break 10:30 – 12:00 Drug Development overview Brian White-Guay, Université de Montréal, Québec 12:00 – 13:15 Lunch 13:15 – 14:45 Molecules and Money: the Business of Drug Development Luc Vachon, Clinical and Product Development Advisor, Ex-CEO Asmacure, Ex-President BioQuébec 14:45 – 15:45 Novel, non obvious, useful? Intellectual property as a discovery engine Steven Lam, PhD, patent agent, ROBIC, S.E.N.C.R.L. 15:45 – 16:15 Plenary discussion with speakers 16:15 – 16:30 Health break 16:30 – 17:30 Visit of IRIC Drug Discovery Platforms (HTS– Medicinal chemistry – SAR– Cytometry) Manon Valiquette, Chief manager, IRIC Scientific & Technology Platforms
TUESDAY, June 16, 2015
Pavilion Jean-Coutu, room S1-111 SESSION II : FROM DRUG TARGET TO NONCLINICAL DEVELOPMENT Chairperson: Jordi Quintana, Parc Centific Barcelona (PCB) 8:45 – 9:45 A molecular pharmacologist's guide to X-ray crystallography Xavier Deupi, Paul Scherrer Institute 9:45 – 10:45 Drug discovery – small molecule Jordi Quintana, Parc Centific Barcelona (PCB) 10:45 – 11:00 Health break 11:00 – 12:00 Chemistry-fabrication-formulation of small molecules / biologics Grégoire Leclair, Université de Montréal 12:00 – 13:15 Lunch 13:15 – 14:15 Current Trends in Non-Clinical Safety Testing Céline Locas, Consultant in Toxicology and Drug Development 14:15 – 15:15 Dendrimers as Drug : from idea to preclinical development Rémy Poupot, Université Paul-Sabatier / INSERM, Toulouse 15:15 – 15:45 Plenary discussion with speakers 15:45 – 16:00 Health break SESSION III : PARTICIPANT MINI-SYMPOSIUM Chairperson: Pierre Cordelier, Université Paul-Sabatier/ INSERM, Toulouse 16:00 – 17:00 Participant short presentations – “How does my current research fit in the context of drug R&D ?”
WEDNESDAY, JUNE 17, 2015
Pavilion Jean-Coutu, room S1-111 SESSION IV: FROM CLINICAL DEVELOPMENT TO MARKET ACCESS Chairperson: Brian White-Guay, Université de Montréal, Québec 8:45 – 9:45 Learning studies : From first in man to proof of concept studies Marc Lefebvre, VP, Algorithme Pharma 9:45 – 10:45 Confirmatory studies Brian White-Guay, Université de Montréal, Québec 10:45 – 11:00 Health break 11:00 – 12:00 Pharmaco-economics and Market Access Jean Lachaine, Université de Montréal, Québec 12:00 – 13:15 Lunch 13:15 – 14:15 Pharmacovigilance and Risk Management Planning Ariel Arias, Senior Advisor, Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Invited professor, Université de Montréal 14:15 – 14:45 Plenary discussion with speakers 14:45 – 15:00 Health break SESSION V : CASE STUDY I – REGULATORY STRATEGIES 15:00 – 17:15 Development of a novel agent for inflammatory liver diseases Patrick Colin, Chief Development Officer, Verlyx Pharma
THURSDAY, JUNE 18, 2015
Pavilion Jean-Coutu, room S1-111 SESSION VI : INDUSTRIAL SYMPOSIUM THE NEW DRUG DEVELOPMENT COLLABORATION LANDSCAPE IN QUÉBEC in collaboration with CiToxLAB Chairperson: Jean-Pierre Moreau, Business development, CiToxLAB North America Inc. Opening Remarks: Jean-Pierre Moreau, Chairman, CiToxLAB 9:30 – 10:15 From academia to the clinic : Discovery of a new molecule that expands stem cells from umbilical cord blood Anne Marinier, Ph.D., IRIC Montréal 10:15 – 10:45 Assessment of Hematotoxicity in Preclinical Studies Virginie Allegret, Ph.D., CiToxLAB 10:45 – 11:00 Health break 11:00 – 11:30 Custom-designed projects to establish the proof of concept of innovation bioactive molecules Esther Millette, Ph.D., Transbiotech, Levis 11:30 – 13:30 Lunch 13:30 – 14:10 Dose concepts for Photodynamic Therapy and other Light based Therapies Lothar Lilge, Ph.D., University Health Network, University of Toronto 14:15- 15:10 Pain peptides for the validation of the treatment of chronic pain using natural drugs Pascal Vachon, Ph.D., Faculté de Médecine vétérinaire, Université de Montréal 15:10 – 15:25 Health break 15:25 – 16:10 gIcare pharma to Inversago: how to reach human proof of efficacy Maxime Ranger, Ph.D., MBA, Drug Development Strategist, Serial Entrepreneur 16:10 – 16:45 Neomed II, a new opportunity for the advancement of Biologics in Quebec Philippe Walker, Ph.D., Neomed Institute Networking cocktail
FRIDAY, JUNE 19, 2015
Pavilion Jean-Coutu, room S1-111 SESSION VII : CASE STUDIES : FROM IDEA TO MARKET Treatment of moderate to severe psoriasis : The challenges that represented this therapeutic area, the chemical, preclinical and clinical development of our treatment and the pharmacoeconomical strategy behind it. Chairperson: Louise Fortier, Université de Montréal, Québec 9:00 – 10:30 Company A Alumni of the Advanced Graduate Diploma in Drug development at Faculty of pharmacy, Université de Montréal : Meryem Bardaoui, Véronick Brûlé Viau, Fanny Desjardins, Vincent Lague, François Péloquin, Sina Pousht-Mashhad and Marc-André Sauriol 10:30 – 10:45 Health break 10-:45 – 12:15 Company B Alumni of the Advanced Graduate Diploma in Drug development at Faculty of pharmacy, Université de Montréal : Yousef Hanna, Mickaël Martinho Lemay, Sania Sanji, Hadi Mazloum, Roxanne Julien, Maria Eugenia Juarez Ugarte, Lyna Benaouda, Ahmedi Mohamed, Chung-Yan Yuen, Aurore Flandrin and Mina Guirguis 12:15 – 13:30 Lunch SESSION: CARING ABOUT CAREERS: NAVIGATING THE ECOSYSTEM OF BIOPHARMA Chairperson: Pierre Cordelier, Université Paul-Sabatier 13:30 – 14:30 Biopharmaceutical Stakeholders: understanding the life science ecosystem Michelle Savoie, CEO, Montréal InVivo 14:30 – 15:30 Career development in the biopharmaceutical sector Luc Vachon, Clinical and Product Development Advisor, Ex-CEO Asmacure, Ex-President BioQuébec 15:30 – 16:00 Plenary discussion with speakers 16:00 – 16:30 SSM7 Wrap-up, Closing comments and Overture towards SSM8 Denis de Blois, Université de Montréal, Québec, Chairman, SSM7 Brian White-Guay, Université de Montréal, Québec Louise Fortier, Université de Montréal, Québec Pierre Cordelier, Université Paul-Sabatier / INSERM, Toulouse Remy Poupot, Université Paul-Sabatier, Toulouse